Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.…
Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
Can-Fite BioPharma (NYSEAMERICAN: CANF) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 1.435 USD on 20 November 2026, down 84.4% over 52 weeks. Its 52-week range is 1.420 USD to 12.40 USD: the price is 88.4% below the high and 1.1% above the low.
Its market capitalisation is 4.35M USD.
Can-Fite BioPharma reports return on equity of -175.8% and flat revenue year over year.
It holds more cash than debt, a net cash position of 6.99M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.